Regeneron Proves Insurmountable As Second FDA Approved Eylea Biosimilar Blocked
Samsung Bioepis Joins Biocon In Feeling Weight Of Injunction; Amgen On Separate Track
Executive Summary
Regeneron’s lynchpin US formulation patent for its Eylea 2mg appears to remain a thorn in the side for biosimilar sponsors, as Samsung Bioepis joins Biocon in being blocked from launching its US FDA-approved biosimilar to the near $6bn eye-disease biologic.